Seventeen years ago EpiVax Inc. spun out of a laboratory at Brown University – a high-risk but high-reward company whose founders had made an innovative discovery. Today the self-funded, Providence-headquartered company is at the forefront of vaccine research. Its computational tools enable developers to engineer and design safe, effective and protective therapeutic proteins and vaccines, and ...

A new blue ribbon study, “A National Blueprint for Biodefense,” endorsed a new strategic direction for medical countermeasures to biothreats, recommending investments in vaccine-on-demand technologies developed by EpiVax. By Richard Asinof WASHINGTON, D.C. – The vaccine on demand technologies pioneered by EpiVax received a major shot in the arm when the Blue Ribbon Study Panel on Biodefense released ...

October 28th – Providence, RI – A report released today by former DHS Secretary Tom Ridge, former US Senator Joseph Lieberman and members of the Blue Ribbon Study Panel on Biodefense (BRSPB) identified “serious gaps and inadequacies that continue to leave the Nation vulnerable to biothreats”. Their comprehensive report on the state of National Biodefense calls ...

Ipsen and EpiVax have announced the completion of a collaborative project that resulted in a “stealth” version of a botulinum neurotoxin derived therapeutic. As foreign proteins, BoNTs have the potential to elicit an immune response reducing therapeutic efficacy. Ipsen is actively developing a platform of novel neurotoxin derived therapeutics, including targeted secretion inhibitors (TSI) that are opening up ...

Even though Ebola has faded into the background, newly emerging infectious disease remain a challenge for the future. Completely new vaccines to prevent infectious diseases, and ancient ones, will be the focus of this year’s edition of the Vaccine Renaissance. For example, Dr. Steven Hoffman of Sanaria will describe clinical trials with his irradiated Malaria ...

Researchers at EpiVax and University of Rhode Island explain H7N9 influenza vaccine failure: Pathogen developed ‘Immune Camouflage’ to hide from human immune response The avian influenza A(H7N9) virus has been a major concern since the first outbreak in China in 2013. Due to its high rate of lethality and pandemic potential, H7N9 vaccine development has become a ...

ONE MORE DAY TO SUBMIT YOUR ABSTRACT! 9th Vaccine Renaissance Conference Providence, RI – November 4-6, 2015 The 9th Annual Vaccine Renaissance Conference planning committee is pleased to invite you to submit an abstract for consideration. This year the focus will be on new methods that will improve vaccine efficacy and safety and on the crucial role ...

Having a hard time keeping up with the EpiVaxer’s?   Click HERE for more information about where we will be in September & October! October 15th → Taipei, Taiwan •Thursday, October 15th: 1st annual Westin Taipei Immunogenicity Seminar (FREE!). Click HERE to register. October 17th-24th → Seoul, Korea •Saturday, October 17th: Computational Vaccinology Workshop (CV5) at 9th Vaccine & ISV Annual ...

MERIDEN, Conn. – Another flu season is fast approaching, and with it, concerns about the potential effectiveness of flu vaccines to combat two strains of flu virus expected to be in circulation, it seemed like a good time to do a story on Protein Sciences and its innovative, FDA-approved flu vaccine, Flublok. The success of Protein ...

A new, optimized vaccine for H7N9 flu could soon move into production. PROVIDENCE – Getting into the clinic has always been a bit of a stumbling block for EpiVax, a creative vaccine design firm headquartered in the former Jewelry District, with its pioneering immuno-informatics tools. Now, EpiVax is on the cusp of getting one of its designed ...

The Centre for Health Protection (CHP) of the China Department of Health is investigating an outbreak of hand, foot and mouth disease (HFMD) at a residential child care center in Causeway Bay, Hong Kong. Affected children tested positive for enterovirus (EV71) which usually causes HFMD. According to researchers Qiben Leng and Annie De Groot, the failure of polio vaccine ...

PROVIDENCE, RI – June 9, 2015 – The Defense Threat Reduction Agency (DTRA) is investing $5.2 Million for the development of a new type of vaccine against Q fever. Academic and industry organizations from around the world, led by Mark Poznansky of the Vaccine and Immunotherapy Center (VIC) and Massachusetts General Hospital and Annie De ...

We invite you to join us for this year’s iteration of the Computational Vaccinology Workshop @ ISV. Register for this event! Abstract submissions for full-length papers and posters are still being accepted – submit your abstracts now. The 5th Computational Vaccinology Workshop at International Society for Vaccines (CV5 @ ISV) is a satellite workshop to be held Saturday, October 17th ...

Anne De Groot, CEO of EpiVax, will testify before the Blue Ribbon Study Panel on Biodefense about encouraging innovative methods for solving existing and new biothreats. View a PDF of Annie’s testimony.

PROVIDENCE, R.I. – March 26, 2015 – The University of Rhode Island’s Institute for Immunology and Informatics is currently accepting fellows to participate in a workshop and training course targeting neglected tropical diseases (NTD) and emerging infectious diseases (EID). The workshop will focus on training NTD/EID researchers interested in using new vaccine design tools developed by Principal ...